Compare Linde PLC (LIN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Regeneron Pharmaceuticals Inc — how do they compare? Linde PLC trades at $490.26 (market cap $227.01B), while Regeneron Pharmaceuticals Inc trades at $790 (market cap $83.19B). The key difference: Linde PLC is far larger — about 2.7× Regeneron Pharmaceuticals Inc's market cap, and Linde PLC pays the higher dividend (1.3%). Which is the better fit depends on your goals.
| LIN | REGN | |
|---|---|---|
Market Cap | $227.01B | $83.19B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $812.27 |
52-Week Low | $389.38 | $545.94 |
Enterprise Value | $250.13B | $77.90B |
Dividend Yield | 1.3% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $489.98, showing minimal daily change. The stock exhibits strong fundamentals with consistent earnings beats, a 20.43% net income margin, and robust cash flow. However, technical indicators signal a bearish short-term trend, with the price near the pivot point of $490. Recent news highlights sustainability leadership and Q1 2026 EPS growth of 10% year-over-year, though a DCF analysis from GuruFocus on June 1, 2026, suggested potential overvaluation at a $327 fair value.
The investment outlook is supported by solid profitability and a bullish analyst consensus with a $553.60 price target, but risks include elevated valuation multiples and increasing debt-to-asset ratios. The stock's near-term direction may hinge on Q3 2026 earnings versus the $4.53 estimate, with technical resistance at $493 posing a challenge to upside momentum.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
